USRE39191E1 - Sonic treatment to selectively reduce the void volume of sintered polymers - Google Patents
Sonic treatment to selectively reduce the void volume of sintered polymers Download PDFInfo
- Publication number
- USRE39191E1 USRE39191E1 US10/075,944 US7594402A USRE39191E US RE39191 E1 USRE39191 E1 US RE39191E1 US 7594402 A US7594402 A US 7594402A US RE39191 E USRE39191 E US RE39191E
- Authority
- US
- United States
- Prior art keywords
- polymer
- sintered
- article
- sintered polymer
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229920000642 polymer Polymers 0.000 title claims abstract description 186
- 239000011800 void material Substances 0.000 title claims abstract description 48
- 239000007788 liquid Substances 0.000 claims abstract description 73
- 239000007787 solid Substances 0.000 claims abstract description 49
- 238000000034 method Methods 0.000 claims abstract description 29
- 210000004369 blood Anatomy 0.000 claims abstract description 18
- 239000008280 blood Substances 0.000 claims abstract description 18
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 238000006243 chemical reaction Methods 0.000 claims description 32
- 230000002829 reductive effect Effects 0.000 claims description 17
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 14
- 239000008103 glucose Substances 0.000 claims description 14
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 239000000701 coagulant Substances 0.000 claims description 7
- 210000002966 serum Anatomy 0.000 claims description 6
- 241001191009 Gymnomyza Species 0.000 claims description 5
- 239000003599 detergent Substances 0.000 claims description 5
- 210000002381 plasma Anatomy 0.000 claims description 5
- 210000003296 saliva Anatomy 0.000 claims description 5
- HLXGRHNZZSMNRX-UHFFFAOYSA-M sodium;3-(n-ethyl-3,5-dimethylanilino)-2-hydroxypropane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CC(O)CN(CC)C1=CC(C)=CC(C)=C1 HLXGRHNZZSMNRX-UHFFFAOYSA-M 0.000 claims description 5
- 210000002700 urine Anatomy 0.000 claims description 5
- 206010036790 Productive cough Diseases 0.000 claims description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 4
- 210000003756 cervix mucus Anatomy 0.000 claims description 4
- 210000000582 semen Anatomy 0.000 claims description 4
- 210000003802 sputum Anatomy 0.000 claims description 4
- 208000024794 sputum Diseases 0.000 claims description 4
- 210000004243 sweat Anatomy 0.000 claims description 4
- 210000001138 tear Anatomy 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- MKARNSWMMBGSHX-UHFFFAOYSA-N m-xylylamine Natural products CC1=CC(C)=CC(N)=C1 MKARNSWMMBGSHX-UHFFFAOYSA-N 0.000 claims 1
- 229920001903 high density polyethylene Polymers 0.000 abstract description 43
- 239000004700 high-density polyethylene Substances 0.000 abstract description 43
- 230000005012 migration Effects 0.000 abstract description 3
- 238000013508 migration Methods 0.000 abstract description 3
- 239000010410 layer Substances 0.000 description 47
- 239000011148 porous material Substances 0.000 description 27
- 238000012360 testing method Methods 0.000 description 22
- -1 polypropylene Polymers 0.000 description 19
- 230000000717 retained effect Effects 0.000 description 12
- 239000002245 particle Substances 0.000 description 11
- 238000003466 welding Methods 0.000 description 11
- 230000000712 assembly Effects 0.000 description 10
- 238000000429 assembly Methods 0.000 description 10
- 239000004743 Polypropylene Substances 0.000 description 7
- 229920001155 polypropylene Polymers 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 6
- 239000000853 adhesive Substances 0.000 description 6
- 230000001070 adhesive effect Effects 0.000 description 6
- 239000012790 adhesive layer Substances 0.000 description 6
- 239000012491 analyte Substances 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000004698 Polyethylene Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 229920001577 copolymer Polymers 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 229920000573 polyethylene Polymers 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000003100 immobilizing effect Effects 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000002861 polymer material Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000007480 spreading Effects 0.000 description 4
- 238000003892 spreading Methods 0.000 description 4
- 239000004699 Ultra-high molecular weight polyethylene Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 108091005996 glycated proteins Proteins 0.000 description 3
- 229940100689 human protein c Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229920000785 ultra high molecular weight polyethylene Polymers 0.000 description 3
- NEGFNJRAUMCZMY-UHFFFAOYSA-N 3-(dimethylamino)benzoic acid Chemical compound CN(C)C1=CC=CC(C(O)=O)=C1 NEGFNJRAUMCZMY-UHFFFAOYSA-N 0.000 description 2
- 101500025568 Homo sapiens Saposin-D Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- IXZISFNWUWKBOM-ARQDHWQXSA-N fructosamine Chemical compound NC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O IXZISFNWUWKBOM-ARQDHWQXSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 238000005245 sintering Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- ZTQGWROHRVYSPW-UHFFFAOYSA-N 3-(n-ethyl-3-methylanilino)-2-hydroxypropane-1-sulfonic acid Chemical compound OS(=O)(=O)CC(O)CN(CC)C1=CC=CC(C)=C1 ZTQGWROHRVYSPW-UHFFFAOYSA-N 0.000 description 1
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N 4-aminoantipyrine Chemical compound CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 102100022977 Antithrombin-III Human genes 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 101001033280 Homo sapiens Cytokine receptor common subunit beta Proteins 0.000 description 1
- 101000577630 Homo sapiens Vitamin K-dependent protein S Proteins 0.000 description 1
- 101000782195 Homo sapiens von Willebrand factor Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 239000004708 Very-low-density polyethylene Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- HLVXFWDLRHCZEI-UHFFFAOYSA-N chromotropic acid Chemical compound OS(=O)(=O)C1=CC(O)=C2C(O)=CC(S(O)(=O)=O)=CC2=C1 HLVXFWDLRHCZEI-UHFFFAOYSA-N 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 108091005995 glycated hemoglobin Proteins 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000013029 homogenous suspension Substances 0.000 description 1
- 102000055647 human CSF2RB Human genes 0.000 description 1
- 102000052932 human PROS1 Human genes 0.000 description 1
- 229960000027 human factor ix Drugs 0.000 description 1
- 229940099816 human factor vii Drugs 0.000 description 1
- 229940034998 human von willebrand factor Drugs 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- SCUZVMOVTVSBLE-UHFFFAOYSA-N prop-2-enenitrile;styrene Chemical compound C=CC#N.C=CC1=CC=CC=C1 SCUZVMOVTVSBLE-UHFFFAOYSA-N 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- IRQRBVOQGUPTLG-UHFFFAOYSA-M sodium;3-(n-ethyl-3-methylanilino)-2-hydroxypropane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CC(O)CN(CC)C1=CC=CC(C)=C1 IRQRBVOQGUPTLG-UHFFFAOYSA-M 0.000 description 1
- 229920000638 styrene acrylonitrile Polymers 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000013077 target material Substances 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- FYZXEMANQYHCFX-UHFFFAOYSA-K tripotassium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxymethyl)amino]acetate Chemical compound [K+].[K+].[K+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O FYZXEMANQYHCFX-UHFFFAOYSA-K 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 229920001866 very low density polyethylene Polymers 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/508—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5023—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures with a sample being transported to, and subsequently stored in an absorbent for analysis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/12—Specific details about manufacturing devices
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/069—Absorbents; Gels to retain a fluid
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0809—Geometry, shape and general structure rectangular shaped
- B01L2300/0825—Test strips
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0887—Laminated structure
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
- B01L2400/0406—Moving fluids with specific forces or mechanical means specific forces capillary forces
Definitions
- the present invention generally relates to methods for altering the physical properties of materials and, more specifically, to methods for sonically treating sintered polymers to selectively reduce their void volume.
- assays are available to monitor medical conditions at home or in a clinical setting. Such assays often use chemically treated test strips that can react with specific analytes in the body fluids of patients. For example, blood glucose levels can be monitored using test strips that react with glucose in blood samples, causing a color change on the strips. By observing the degree of color change, patients under a diabetes-management regimen can monitor their glucose levels. If the levels are abnormally high, they can then take appropriate steps such as diet management or self-administration of insulin. Failure to monitor glucose levels can result in high glucose levels, leading to cardiovascular disease and degeneration of the kidneys, retinas and nervous system.
- the layer can be said to be a “receiving layer” for absorbing the liquid sample and allowing it to migrate to the test strip.
- the present invention provides a method for selectively reducing the void volume of a sintered polymer by sonic treatment.
- the sonic treatment is effective under a variety of conditions, for example between 15 and 50 kHz and between 10 and 1000 Joules per cubic centimeter of polymer, depending on the composition, shape and arrangement of the sintered polymer.
- Useful sintered polymers include polypropylene, polyvinylidene fluoride, ethylenevinyl acetate, styreneacrylonitrile, polytetrafluoroethylene and related copolymers.
- a particularly useful sintered polymer is porous high density polyethylene (HDPE).
- HDPE and other sintered polymers have pores in a range of effective diameters, such as between 5 and 300 microns.
- Such sintered polymers are also useful in a variety of shapes, such as in the form of substantially planar sheets.
- the void volume can be differentially reduced by immobilizing the sintered polymer against a solid during sonic treatment.
- a first portion of the sintered polymer can be immobilized against a solid during sonic treatment, while a second portion is not.
- the second portion can overlie a window in the solid, so it is not immobilized during the sonic treatment.
- the void volume of the first portion becomes less than in the second portion.
- the invention also provides an article of manufacture for receiving a liquid sample, where a first portion 1 a of a sintered polymer overlies a solid 4 a and a second portion 1 b of the sintered polymer overlies a window 4 b in the solid.
- the void volume of the first portion 1 a becomes less than the void volume of the second portion 1 b.
- the article can also include a means for adhering 3 the sintered polymer to the solid.
- the article is useful for receiving a liquid sample such as blood, and also body fluids such as serum, plasma, sweat, tears, saliva, semen, cerebrospinal fluid, sputum, urine and cervical mucus or swabbings.
- body fluids such as serum, plasma, sweat, tears, saliva, semen, cerebrospinal fluid, sputum, urine and cervical mucus or swabbings.
- the usefulness of the article is enhanced if the surface of the sintered polymer is hydrophilic, for example by being coated with detergent.
- the sintered polymer can also be treated with a coagulant to remove blood cells from the sample.
- the article can further comprise a means for reacting 2 with a liquid sample, which can be positioned between the sintered polymer 1 and the window 4 b of the solid.
- the reacting means can be a reaction layer containing reagents that can react with specific analytes in the liquid sample. For example, N-ethyl-N-2-hydroxy-3-sulfopropyl-3,5-dimethylaniline (MAOS) reacts with glucose to form a color change, which can be observed by a monitor 5 .
- MAOS N-ethyl-N-2-hydroxy-3-sulfopropyl-3,5-dimethylaniline
- the present invention further provides a method for receiving a liquid sample using the article described above.
- a liquid sample when a liquid sample is applied, the sample is received by the sonically treated polymer 1 , migrating preferentially through the second portion 1 b to reach the reaction layer, rather than spreading laterally to the first portion 1 a, where it can be retained.
- less sample is retained in the void volume of the sintered polymer 1 , thereby reducing the volume of liquid sample required to use the article.
- FIG. 1 shows a cross-sectional view of a layer of sintered HDPE.
- the right side of the HDPE has been sonically treated, while the left side is untreated.
- FIG. 2 shows an exploded isometric view of an article of manufacture.
- FIGS. 3A and 3B show cross-sectional partial views of an article of manufacture for receiving a liquid sample.
- FIG. 3A shows the article before sonic treatment.
- FIG. 3B shows the article after sonic treatment.
- the arrows represent the general direction and relative volume of migration by a liquid sample applied to the sintered polymer of the assembly.
- the present invention provides a method of sonic treatment to selectively reduce the void volume of a sintered polymer.
- a polymer is “sintered” when separate particles of polymer material are partially fused to form a porous mass.
- Polymer particles are typically sintered by compression or heating without completely crushing or melting the particles. Because the particles are only partially fused, some of the spaces between the individual particles remain after the sintering process. The result is a porous polymer material containing a network of channels (see FIG. 1 ).
- a porous polymer can therefore be useful as a filter to trap fine solid particulates, while allowing liquids and gases to pass through the network of channels.
- sintered polymers are useful for wicking and absorbing liquids into the channels of the polymer by capillary action. In these applications, however, the original liquid can never be completely recovered because a certain amount of the liquid is retained in the interconnected channels of the polymer.
- the volume of liquid that a sintered polymer can absorb into its interconnected spaces is generally related to the void volume.
- the term “void volume” refers to the volume of the spaces between the partially fused particles. Thus, the greater the void volume, the more liquid is retained by the sintered polymer.
- Such disruption is achieved by subjecting the sintered polymer to “sonic treatment,” which directs vibrational sound energy at high frequencies against the polymer.
- the method of the invention therefore reduces the void volume of a sintered polymer by sonically treating its structure, and is useful for controlling the rate of wicking and absorptive properties of the polymer.
- Devices for sonic treatment are commercially available, for example from Sonics & Materials, Inc. (Danbury, Conn.). Herrmann Ultrasonics Inc. (Schaumburg, Ill.) and Branson Ultrasonics (Singapore). The Ultra-Com Model 210 from Dukane Ultrasonics (St. Charles, Ill.) is particularly useful. Such devices typically direct the sonic energy to the target via a welding horn applying uniform pressure, for example at 70 or 88 psi.
- the energy must be sufficiently great to disrupt the structure of the sintered polymer.
- the amount of energy required is expressed in terms of the amount of sonic energy directed to a given volume of sintered polymer.
- the sonic treatment should direct at least 10 Joules per cubic centimeter of sintered polymer (J/cc) to effectively disrupt the sintered structure of a polymer.
- the sonic treatment is also effective at greater than 20, 50, 100, 200 and 500 J/cc.
- the sonic energy should not be so great as to melt the sintered polymer or to cause the polymer to become dislodged by the vibrations during treatment.
- the sonic treatment per treatment should be less than 1000 J/cc, or alternatively less than 900, 800, 700, 600 or 500 J/cc.
- the sonic energy was 347 J/cc, which effectively reduced the void volume of the polymer without melting.
- the disruption of a sintered polymer can also be affected by the frequency of the sound waves, which is measured in kilohertz (kHz).
- kHz kilohertz
- the frequency of sound waves can vary in actual use, depending on several factors, including the instrument used, damping caused by the target material and fluctuations in the power source. Therefore, the frequency is best described in approximate terms.
- the frequency of the sonic treatment is effective from a lower range of about 15 to 20 kHz to an upper range of about 40 to 50 kHz.
- the duration of the sonic treatment can also vary, depending on the energy, frequency and sintered polymer, but is effective when applied for about 0.2, 0.5, 1, 2 or 5 seconds.
- Effective conditions for sonic treatment are ascertained by one skilled in the art by testing various parameters on a sintered polymer and determining whether the sonic treatment has physically disrupted the sintered structure of the polymer without melting or dislodging it. Whether the disruption is sufficient to reduce the void volume is readily determined by microscopic inspection, as described in Example I, or by the drop-absorption method provided in Example II.
- the conditions for sonic treatment will vary, of course, depending on the composition, shape and arrangement of the sintered polymer.
- polymers that are sintered by the method of the invention include polypropylene, polyvinylidene fluoride, ethylenevinyl acetate, styreneacrylonitrite and polytetrafluoroethylene, for example POREX X-4908 sintered polypropylene (Porex Technologies; Fairburn, Ga.).
- POREX X-4908 sintered polypropylene Porex Technologies; Fairburn, Ga.
- Other useful sintered polymers are obtained by combining or copolymerizing more than one type of polymer material into a copolymer to optimize strength, heat, corrosion or abrasion-resistance properties.
- POREX X-4105 SCP is a sintered copolymer of 95% polypropylene and 5% polyethylene (Porex Technologies; Fairburn, Ga.).
- a useful polymer is sintered polyethylene, which is available as ultra high molecular weight polyethylene, high density polyethylene (HDPE), low density polyethylene or very low density polyethylene (all from GenPore; Reading, Pa.).
- Particularly useful forms of sintered polyethylene are POREX XM-1342 sintered high density polyethylene, POREX X-4913 sintered high density polyethylene coarse sheet; and POREX X-4908 sintered polypropylene medium sheet and POREX X-4900 sintered ultra high molecular weight polyethylene (all from Porex Technologies; Fairburn, Ga.).
- Sintered HDPE and other polymers useful in the invention can have a variety of pore sizes. Pore sizes are described in terms of “effective diameter,” which measures the ability of particles of a predetermined diameter to pass through the porous substance, even though the pores and the passages may be irregular. Moreover, because the size of the pores can be nonuniform, they can be described in terms of an average effective pore diameter or as a range of effective pore diameters.
- Average pore sizes can be measured on a Mercury Intrusion Porisimeter (Micromeretics; Norcross, Ga.).
- the sintered HDPE can be extra fine with an average effective diameter of 27 microns; fine with an average effective diameter of 69 microns; medium with an average effective diameter of 119 microns; and coarse with an average effective diameter of 167 microns (available from Porex Technologies as part numbers 4920, 4900, 4903 and 4732, respectively).
- a particularly useful sintered polymer can have pores of an effective diameter between 5 and 300 microns.
- Other useful ranges for the effective diameter of pores can have a lower value of 0.5, 1, 2, 10, 25, and 50 microns and an upper value of 20, 50, 100, 500 and 1000 microns.
- the pore sizes can also be affected, typically reducing the pore sizes or making the pore size distribution more uniform.
- the sonic treatment can also be useful for selectively modifying the pore sizes of the sintered polymer.
- sonic treatment can be selectively directed at specific portions of the polymer to reduce the pore sizes of a desired area of the polymer.
- a sintered polymer can be sonically treated at different intensities at various portions of the polymer to create a filter with selected pore sizes within the polymer.
- a sintered polymer can be sonically treated with more intensity toward the bottom and less intensity at the top, resulting in a gradient filter.
- the gradient filter will therefore have relatively wide pores at the upper portion and progressively narrower pores toward the bottom. If a sample containing heterogenous particles is applied to the gradient filter, larger particulates are trapped in the upper portion, smaller particulates in the lower portions, and the smallest particulates allowed to pass through the filter. If desired, the filter can then be sliced into sections to retrieve the particulates, sorted according to size.
- the sonic treatment of the invention allows pores in a sintered polymer to be selectively manipulated according to size and location within the polymer (see Example II).
- the conditions of the sonic treatment can also be affected by the shape of the sintered polymer.
- Various shapes are useful, such as an elongated form so that the sintered polymer can serve as a slender wick for liquids.
- the sintered polymer can also be “substantially planar,” as in the form of a thin flat sheet.
- POREX XM-1342 HDPE is supplied in sheets between 0.024 and 0.028 of an inch thick.
- the sonic treatment should direct at least 1 Joule per square centimeter of sintered polymer (J/sc) to effectively disrupt the sintered structure of the polymer.
- the sonic treatment can also be effective at greater than 2, 5, 10, 20 and 30 J/sc.
- the sonic treatment per treatment should also be less than 50 J/sc, or alternatively, less than 45, 40, 35 or 30 J/sc. For example, when 600 Joules was directed against a 17 ⁇ 1.6 cm area of sintered polymer in sheet form, the sonic energy was 22 J/sc, which effectively reduced the void volume of the polymer without melting.
- the effectiveness of the sonic treatment is enhanced if the sintered polymer is “immobilized” during the sonic treatment: the polymer is fixed to a solid to decrease its ability to vibrate independently of the solid.
- An immobilized sintered polymer need not be in direct contact with the solid; for example, the sintered polymer can be immobilized to the solid by an adhesive between the polymer and the solid.
- the polymer By immobilizing the sintered polymer to a solid, the polymer vibrates less during sonic treatment, thereby retaining the sonic energy to disrupt the internal structure of the polymer.
- the sonic energy may cause the polymer to vibrate, dispersing a fraction of the sound energy as kinetic or thermal energy rather than causing the desired disruption of the polymer.
- immobilizing or not immobilizing the sintered polymer during sonic treatment can be used to control the level of disruption, consequently controlling the reduction of the void volume in the polymer.
- the solid need not be immobilized before or after the sonic treatment.
- the sintered polymer can be temporarily immobilized against a solid during the sonic treatment by pressing the polymer against a solid surface. After the sonic treatment, the solid surface can be removed so that the polymer is no longer immobilized.
- Whether the sintered polymer is immobilized during sonic treatment can also be used to control the reduction of void volume for one portion of the polymer compared to another portion.
- a first portion of the sintered polymer can be immobilized against a solid during sonic treatment, while a second portion is not.
- the void volume in the first portion becomes less than in the second portion.
- Selectively reduction of the void volume in portions of a sintered polymer is illustrated in FIG. 2 .
- a sintered polymer 1 can overlie a solid 4 having a window 4 b.
- the “window” 4 b can be a hole, a recess, a discontinuity or a space between two separate solids—so long as a portion of a solid is not immobilized against a portion of the polymer.
- a first portion 1 a of the sintered polymer overlies the portion of the solid without the window 4 a and a second portion 1 b overlies the window 4 b on the solid.
- the first portion of the sintered polymer 1 a becomes disrupted because it is immobilized against the solid 4 a.
- the second portion of sintered polymer 1 b overlies the window 4 b, which relieves a portion of the sonic energy, so there is less disruption of that portion 1 b of the sintered polymer.
- the sonic treatment disrupts the sintered structure of the first portion 1 a more than the second portion 1 b, so that the void volume of the first portion 1 a is less than the void volume of the second portion 1 b.
- the level of disruption can be manipulated by adjusting the degree of immobilization of the sintered polymer to the solid. For example, complete immobilization of the polymer against a solid maximizes the disruption caused by sonic energy. As discussed above, however, failure to immobilize the polymer results in dispersal of the energy through vibration or heat. However, partial immobilization can be used to obtain intermediate levels of disruption.
- the gradient filter discussed above can also be obtained by varying the degree of immobilization of a sintered polymer during sonic treatment: not immobilized at an upper portion, moderately immobilized at a middle portion, and strongly immobilized at a bottom portion.
- Sonic treatment therefore allows the selection of the shape of the area with reduced void volume.
- a sheet of sintered polymer can overlie a solid with an elongated channel.
- the portion of the polymer overlying the solid will have reduced void volume, but the portion overlying the channel during sonic treatment will be relatively unaffected.
- the sintered polymer will have an elongated track of relatively greater void volume. If a liquid sample is applied to one end of the track, it will migrate preferentially along the track, rather than spread to the sonically treated areas of the polymer, which have reduced void volume.
- a Y-shaped track can be obtained by sonically treating a sintered polymer immobilized against a solid mold containing a Y-shaped channel.
- a liquid sample is applied to the base of the Y-shaped track after sonic treatment, the sample can migrate upward and be diverted into two separate areas, such as for independent glucose and a fructosamine analyses. Similar methods can be applied to make an article of manufacture to receive a liquid sample.
- the present invention also provides an article of manufacture for receiving a liquid sample.
- the article is useful for providing a receiving layer to quickly absorb a liquid sample, while minimizing the amount of sample retained by the receiving layer.
- the article comprises a solid 4 having a window 4 a and a layer of sintered polymer 1 , where a first portion 1 a of the polymer overlies the surface 4 a of the solid without the window and a second portion 1 b of the polymer overlies the window 4 b of the solid.
- the sintered polymer is sonically treated, the void volume of the first portion 1 a becomes less than the void volume of the second portion 1 b.
- FIG. 2 One embodiment of the example is shown in an exploded view in FIG. 2 .
- a liquid sample is applied on the upper surface of the sintered polymer 1 . Because of the porous structure of the sintered polymer, the liquid is readily absorbed into the interconnected spaces of the polymer (see Example II). As the liquid is absorbed, it migrates by capillary action through the sintered polymer material. The capillary action is more rapid where the void volume is greater within the sintered polymer. Thus, where one portion of the sintered polymer has selectively reduced void volume relative to another, the liquid will tend not to migrate through the portion with reduced void volume. Consequently, sonic treatment allows the liquid preferentially migrates through the second portion of the polymer and more sample will migrate downward toward the window 4 b.
- the void volume is the same throughout the sintered polymer, as depicted in FIG. 3 A.
- the sample migrates downward toward the window 4 b.
- a significant fraction of the sample tends to spread laterally through the sintered polymer, where it is retained in the periphery of the polymer 1 b. Therefore, in applications where sample migration toward the window is desirable, less sample need be applied to sonically treated articles than untreated articles to obtain equivalent volumes of sample migrating toward the window 4 b.
- the article can also comprise a “means for adhering” the sintered polymer to the solid.
- the adhering means can be acrylic-, rubber- or silicon-based adhesives.
- a particularly useful acrylic-based adhesive layer is FAS-TAPE 8311 double-coated acrylic-based adhesive (Avery-Dennison, Inc.; Pasadena, Calif.).
- Other adhesives include 3M 444 or 3M 415 double-coated adhesives (3M; Minneapolis, Minn.).
- Means for adhering the sintered polymer to the solid can also include PVC plastic pipe cement, epoxy, heat staking, clamping, bolting, nailing, compression fitting and immobilization by vacuum. The positioning of the adhering means is not critical as long as the sintered polymer is securely fixed to the solid.
- a adhering means has been incorporated into the assembly as a adhesive layer 3 between the sintered polymer 1 and the solid support 4 .
- the sonic treatment has the further benefit of welding a tight seal between the sintered polymer, the adhesive layer and the solid. The tight seal ensures that the article remains assembled when used to receive a liquid sample.
- the “liquid sample” to be applied to the sintered polymer encompasses any fluid containing an analyte to be measured.
- the term encompasses blood, serum or plasma.
- the term also encompasses other patient specimens such as sweat, tears, saliva, semen, cerebrospinal fluid, sputum, urine and cervical mucus or swabbings.
- the term further encompasses food, environmental or industrial samples, depending on the desired application of the article, as long as they are liquid and contain an analyte for measurement.
- the liquid sample can be analyzed for specific analytes, which is any substance to be detected or quantitated in terms of concentration.
- the analyte can be glucose, fructose, or other sugars, cholesterol, ketones, lipids, uric acid or specific amino acids such as phenylalanine.
- the analyte can also be proteins, for example enzymes such as amylase, creatine kinase or alanine aminotransferase.
- the analyte can be glycated proteins, for example serum or plasma glycated protein as measured by fructosamine, or red blood cell glycated protein as measured by glycated hemoglobin, in particular Hb A1C .
- Other analytes are described in U.S. Pat. No. 5,597,532, incorporated herein by reference.
- the article When used as a test strip device to receive and analyte liquid samples, the article is particularly effective when the surfaces of the sintered polymer are hydrophilic so that the polymer can readily wick the liquid sample.
- the sintered polymer composition itself is not inherently hydrophilic, the polymer can be rendered hydrophilic by incorporating hydrophilic or amphipathic components into the composition before sintering.
- the surfactant ethane-sulfonic acid 2-(methyl(1-oxo-9-octadecenyl)amino), sodium salt can be incorporated into polyethylene so that the final sintered product is hydrophilic.
- a polymer After a polymer is sintered, it can also be treated with a “coating” so that a layer of detergent covers the outside surfaces as well as the surfaces within the sintered structure of the polymer, rendering the polymer more hydrophilic.
- sintered HDPE can be treated with a detergent such as polyoxypropylene polyoxyethylene block copolymer (Pragmatics Inc.; Oak Ridge, Tenn.) or MAPHOS 66 phosphate esters (Mazer Chemical; Gurnee, Ill.).
- a particularly useful treatment is soaking sintered HDPE in an aqueous solution of 20% isopropanol and 0.03% TWEEN-20 polyoxyethylene(20)sorbitan monolaurate (Calbiochem; La Jolla, Calif.).
- the sintered polymer can be further treated with a coagulant to remove blood cells from the sample.
- a “coagulant” is a material that causes a homogenous suspension of particle, such as red blood cells, to agglomerate into larger masses, which can be removed by settling or filtration.
- the sintered polymer can be coated using a solution containing 0.15% hexadimethrin in a 0.85% NaCl solution. The use of coagulants to confer blood-separation properties to such polymers is disclosed in greater detail in U.S.
- coagulants useful in the invention include anti-thrombin III, factor V, factor VII, human factor IX, human factor X, human fibrogen, fibrogen from whole serum, human protein C, human protein C alkaline phosphatase conjugate, human beta-protein C, human protein S and human von Willebrand factor.
- the article can further comprise a “means for reacting” with a liquid sample: a means that can react with specific analytes in a liquid sample.
- a representative means for reacting with glucose is the reaction layer disclosed in Example III, which is a porous nylon membrane treated with reactants.
- Other representative reaction layers are described in U.S. Pat. No. 5,470,752, U.S. Pat. No. 5,597,532 and U.S. Pat. No. 5,695,949, each incorporated herein by reference.
- Another type of means for reacting with the liquid sample is a layer that can result in a detectable electrochemical change upon reaction with the liquid sample. Such means are described in U.S. Pat. No. 5,639,672, incorporated herein by reference.
- a reacting means is incorporated into the assembly as a reaction layer 2 between the sintered polymer 1 and the solid support 4 .
- a liquid sample applied to the sintered polymer 1 will migrate preferentially through the second portion 1 b of the polymer until it reaches the reaction layer 2 , allowing the sample to react with any reactants present on the reaction layer.
- the reacting means need not be positioned between the sintered polymer and the solid support, however.
- the reacting means can be positioned below the solid 4 , as long as the liquid sample can migrate to the reaction layer and any resulting reaction is observed.
- a particularly useful reaction layer contains a reagent that reacts with glucose in the liquid sample.
- Typical reagents for reacting with glucose include N-ethyl-N-2-hydroxy-3-sulfopropyl-3,5-dimethylaniline (MAOS) and N-ethyl-N-(2-hydroxy-3-sulfopropyl)-m-toluidine (TOOS).
- reagents include the combination of 4-aminoantipyrene and chromotropic acid (AAP-CTA) and the combination of 3-methyl-2-benzothiazoline hydrazone hydrochloride (MBTH) and either 3-dimethylaminobenzoic acid (DMAB) or 8-anilo-1-napthalenesulfonate (ANS).
- AAP-CTA 4-aminoantipyrene and chromotropic acid
- MBTH 3-methyl-2-benzothiazoline hydrazone hydrochloride
- DMAB 3-dimethylaminobenzoic acid
- ANS 8-anilo-1-napthalenesulfonate
- the present invention provides a method for receiving a liquid sample.
- the sample preferentially migrates through the sintered polymer toward the window, rather than spreading to peripheral areas of the sintered polymer having a reduced void volume. Consequently, less sample need be applied to obtain the desired volume of sample from the sintered polymer (see Example III).
- FIG. 1 shows a microscopic cross-section at 40 ⁇ magnification of POREX XM-1342 sintered high density polyethylene (HDPE) (Porex Technologies; Fairburn, Ga.).
- the HDPE was supplied in sheets 0.0635 cm thick.
- a portion of the HDPE was then sonically treated as follows.
- a Dukane Ultrasonics welding press (St. Charles, Ill.) was used, having a 6.75′′ ⁇ 0.625′′ (17.1 cm ⁇ 1.6 cm) welding horn. The welding horn pressed against the HDPE at 88 psi. The welding press then directed 1200 Joules of sonic energy for 1 second at 20 kilohertz to the 6.75′′ ⁇ 0.625′′ area under the welding horn, resulting in sonic treatment of 559 J/cc.
- FIG. 1 shows a microscopic cross-section of a layer of sintered HDPE.
- the right side of the HDPE has been sonically treated, while the left side is not treated.
- the sonic treatment has disrupted the sintered structure of the right side of the HDPE, compared to the untreated left side. As a result, the volume of the interconnected spaces between the individual sintered particles is decreased.
- sonic treatment is effective for reducing the void volume of the sintered polymers.
- the thickness of the HDPE is visibly reduced, thereby increasing the density of the HDPE layer.
- Sintered HDPE was previously considered a relatively noncompressible layer that returns to its original thickness after compression.
- the sonic treatment method is also useful for compressing a sintered polymer such as HDPE.
- Reduction in void volume can also be demonstrated by measuring the time required for a sintered polymer to absorb a given volume of liquid.
- a sintered polymer that has reduced void volume will not absorb a liquid sample as readily as an untreated polymer because the sintered structure of the treated polymer has been disrupted by sonic energy.
- POREX XM-1342 sintered high density polyethylene POREX X-4105 SCP sintered co-polymer sheet
- POREX X-4900 sintered ultra high molecular weight polyethylene 15 to 45 micron pore size
- POREX X-4913 sintered high density polyethylene coarse sheet 90 to 130 micron pore size
- POREX X-4908 sintered polypropylene medium sheet 120 micron average pore size (all from Porex Technologies; Fairburn, Ga.).
- the sintered polymers were sonically treated as follows.
- a Dukane Ultrasonics welding press (St. Charles, Ill.) was used, with the welding horn pressed against the sintered polymer at 88 psi.
- the welding press then directed sonic energy for 1 second at 20 kilohertz, resulting in sonic treatment of 559 J/cc.
- the energy of the sonic treatment was varied from 0 J, as a control, to 1200 J.
- EDTA tripotassium ethylenediaminetetraacetate
- This example describes the sonic treatment of sintered polymer incorporated into a test strip assembly.
- sonic treatment of the test strip assembly reduces the void volume of the sintered polymer, and consequently the volume of liquid sample needed to be applied to the assembly.
- This example describes a test strip assembly incorporating sintered HDPE.
- a solid polyester support 4 having a circular window 4 b was used as a solid base for the assembly.
- a layer of FAS-TAPE 8311 double-coated acrylic-based adhesive 3 (Avery-Dennison, Inc.; Pasadena, Calif.) was applied to the support 4 around the area of the window 4 a.
- the reaction layer was impregnated with a glucose oxidase/horseradish peroxidase system (Toyobo Inc.; Tokyo, Japan) and MAOS (N-ethyl-N-2-hydroxy-3-sulfopropyl-3,5-dimethylaniline, sodium salt, monohydrate) (Dojindo Laboratories; Kumamoto, Japan).
- a glucose oxidase/horseradish peroxidase system Toyobo Inc.; Tokyo, Japan
- MAOS N-ethyl-N-2-hydroxy-3-sulfopropyl-3,5-dimethylaniline, sodium salt, monohydrate
- hydrophilic POREX XM-1342 sintered high density polyethylene (HDPE) 1 was positioned over the reaction layer 2 , completely covering the reaction layer and in contact with the adhesive layer 3 .
- the HDPE had been previously treated with between 0.0001% and 0.1% PLURONIC polyoxypropylene polyoxyethylene block copolymer (Pragmatics Inc.: Oak Ridge, Tenn.), 8% mannitol, and 0.15% hexadimethrin, all in a 0.85% NaCl solution.
- Example II The assemblies were then sonically treated as described in Example I, except at 70 psi and 200 Joules of energy, effectively welding the assembly together. Control assemblies were pressed at 70 psi, but were not subjected to sonic treatment.
- the assemblies were tested for their ability to receive a liquid sample and allow the sample to migrate through the HDPE and reach the reaction layer. Failure of a sample to reach the reaction layer indicated that a significant portion of the sample had been retained in the HDPE layer. As disclosed above, such retention can result from lateral spreading of the sample to the periphery of the HDPE. Lateral spreading is reduced, however, by sonic treatment to reduce the void volume of selected portions of the HDPE. Consequently, the assemblies were tested for selectively reduced void volume by testing whether a liquid sample was sufficient to successfully wet the underlying reaction layer.
- Changes in reflectance were detected by directing 635 nm light from a light-emitting diode through the window to the reaction layer surface. Changes in the level of diffuse reflected light back through the window were then detected by a silicon photodiode to indicate wetting of the reaction layer.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Clinical Laboratory Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
| Sonic energy | Seconds to absorb | ||
| 0 | J = | 0 | J/cc | 0.358 | ||
| 300 | J = | 174 | J/cc | 0.634 | ||
| 600 | J = | 384 | J/cc | 0.836 | ||
| 900 | J = | 521 | J/cc | 1.084 | ||
| 1200 | J = | 695 | J/cc | 2.038 | ||
POREX X-4105 SCP sintered co-polymer sheet:
| Sonic energy | Seconds to absorb | ||
| 0 | J = | 0 | J/cc | 0.545 | ||
| 1200 | J = | 695 | J/cc | 1.956 | ||
POREX X-4900 sintered ultra high mol. wt. polyethylene:
| Sonic energy | Seconds to absorb | ||
| 0 | J = | 0 | J/cc | 0.569 | ||
| 1200 | J = | 695 | J/cc | 1.065 | ||
POREX X-4913 high density polyethylene coarse sheet:
| Sonic energy | Seconds to absorb | ||
| 0 | J = | 0 | J/cc | 0.468 | ||
| 1200 | J = | 695 | J/cc | 1.547 | ||
POREX X-4908 sintered polypropylene medium sheet:
| Sonic energy | Seconds to absorb | ||
| 0 | J = | 0 | J/cc | 0.300 | ||
| 1200 | J = | 695 | J/cc | 0.563 | ||
These results demonstrate that sonic treatment slows the ability of various sintered polymers to absorb a liquid sample. As shown below, the ability to selectively slow absorption of a liquid is used to control the volume and direction of flow of a liquid sample in a test strip device.
| volume of | ||||
| sample applied | sonic | fraction of assemblies | ||
| wetted | treatment | where the strip was | ||
| 5 μl | no | 0/10 = 0% | ||
| 10 μl | no | 1/10 = 10% | ||
| 5 μl | yes | 10/10 = 100% | ||
| 10 μl | yes | 10/10 = 100% | ||
As shown by the results, 5 and 10 μl samples were sufficient to wet the reaction layers in all the sonically treated assemblies, but almost none of the untreated assemblies. Accordingly, sonic treatment enables the reaction layer in such assemblies to be reliably wetted with 10 μl or even 5 μl of sample.
Claims (24)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/075,944 USRE39191E1 (en) | 1998-01-14 | 2002-02-14 | Sonic treatment to selectively reduce the void volume of sintered polymers |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/006,787 US6024919A (en) | 1998-01-14 | 1998-01-14 | Sonic treatment to selectively reduce the void volume of sintered polymers |
| US10/075,944 USRE39191E1 (en) | 1998-01-14 | 2002-02-14 | Sonic treatment to selectively reduce the void volume of sintered polymers |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/006,787 Reissue US6024919A (en) | 1998-01-14 | 1998-01-14 | Sonic treatment to selectively reduce the void volume of sintered polymers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| USRE39191E1 true USRE39191E1 (en) | 2006-07-18 |
Family
ID=21722580
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/006,787 Ceased US6024919A (en) | 1998-01-14 | 1998-01-14 | Sonic treatment to selectively reduce the void volume of sintered polymers |
| US10/075,944 Expired - Lifetime USRE39191E1 (en) | 1998-01-14 | 2002-02-14 | Sonic treatment to selectively reduce the void volume of sintered polymers |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/006,787 Ceased US6024919A (en) | 1998-01-14 | 1998-01-14 | Sonic treatment to selectively reduce the void volume of sintered polymers |
Country Status (1)
| Country | Link |
|---|---|
| US (2) | US6024919A (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6656741B1 (en) * | 1999-03-03 | 2003-12-02 | Diabetes Diagnostics, Inc. | Air gap for controlling sample absorption and hematocrit dependence |
| US20060019406A1 (en) * | 2004-07-23 | 2006-01-26 | Ning Wei | Lateral flow device for the detection of large pathogens |
| US20060068500A1 (en) * | 2004-09-28 | 2006-03-30 | Kimberly-Clark Worldwide, Inc. | Detecting yeast infections using a lateral flow assay |
| CN101688835B (en) * | 2007-06-28 | 2014-01-29 | 皇家飞利浦电子股份有限公司 | Microelectronic sensor device for optical inspection of wetted surfaces |
| US10436773B2 (en) | 2016-01-18 | 2019-10-08 | Jana Care, Inc. | Mobile device based multi-analyte testing analyzer for use in medical diagnostic monitoring and screening |
| US11536732B2 (en) | 2020-03-13 | 2022-12-27 | Jana Care, Inc. | Devices, systems, and methods for measuring biomarkers in biological fluids |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4300910A (en) * | 1979-11-30 | 1981-11-17 | Dragerwerk Aktiengesellschaft | Test vial construction and method of measuring gas, vapor and aerosol components in an air sample |
| US5470752A (en) * | 1994-06-29 | 1995-11-28 | Lxn Corporation | Multi-layer devices and methods of assaying for fructosamine |
| WO1996031270A1 (en) * | 1995-04-07 | 1996-10-10 | Lxn Corporation | Whole blood separation method and devices |
| US5597532A (en) * | 1994-10-20 | 1997-01-28 | Connolly; James | Apparatus for determining substances contained in a body fluid |
| US5639672A (en) * | 1995-10-16 | 1997-06-17 | Lxn Corporation | Electrochemical determination of fructosamine |
| US5695949A (en) * | 1995-04-07 | 1997-12-09 | Lxn Corp. | Combined assay for current glucose level and intermediate or long-term glycemic control |
-
1998
- 1998-01-14 US US09/006,787 patent/US6024919A/en not_active Ceased
-
2002
- 2002-02-14 US US10/075,944 patent/USRE39191E1/en not_active Expired - Lifetime
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4300910A (en) * | 1979-11-30 | 1981-11-17 | Dragerwerk Aktiengesellschaft | Test vial construction and method of measuring gas, vapor and aerosol components in an air sample |
| US5470752A (en) * | 1994-06-29 | 1995-11-28 | Lxn Corporation | Multi-layer devices and methods of assaying for fructosamine |
| US5597532A (en) * | 1994-10-20 | 1997-01-28 | Connolly; James | Apparatus for determining substances contained in a body fluid |
| WO1996031270A1 (en) * | 1995-04-07 | 1996-10-10 | Lxn Corporation | Whole blood separation method and devices |
| US5695949A (en) * | 1995-04-07 | 1997-12-09 | Lxn Corp. | Combined assay for current glucose level and intermediate or long-term glycemic control |
| US5639672A (en) * | 1995-10-16 | 1997-06-17 | Lxn Corporation | Electrochemical determination of fructosamine |
Also Published As
| Publication number | Publication date |
|---|---|
| US6024919A (en) | 2000-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0272043B1 (en) | Diagnostic device | |
| US6106779A (en) | Lysis chamber for use in an assay device | |
| US6074869A (en) | Fibrous web for processing a fluid | |
| CA1322335C (en) | Process and device for the separation of a body fluid from particulate materials | |
| JP3830715B2 (en) | Multi-layer analyzer | |
| EP0272044B1 (en) | Vacuum diagnostic device | |
| US7605004B2 (en) | Test strip for a lateral flow assay for a sample containing whole cells | |
| US4906439A (en) | Biological diagnostic device and method of use | |
| US5296192A (en) | Diagnostic test strip | |
| JP3477555B2 (en) | Combination reagent holding and testing equipment | |
| EP0373863B1 (en) | Analytical test device | |
| EP0638805A2 (en) | Analyte detection device and process | |
| JP2012008136A (en) | Control flow assay apparatus and method | |
| CN1256754A (en) | Analytical Devices for Thin Film-Based Assays | |
| JPH03205563A (en) | Device and method for separating plasma or serum from whole blood | |
| CN100412549C (en) | Adhesive films retaining porosity and bioactivity in assay devices for measuring serum high-density lipoprotein-associated cholesterol | |
| CN106796232A (en) | Lateral flow assay device with filtered flow control | |
| USRE39191E1 (en) | Sonic treatment to selectively reduce the void volume of sintered polymers | |
| WO2001024931A1 (en) | Capillary device for separating undesired components from a liquid sample and related method | |
| CN87102885A (en) | biological diagnostic device | |
| JP3285451B2 (en) | Analysis method and analysis element for whole blood sample | |
| JPH0755810A (en) | Device and method for detecting body under test | |
| WO2000052468A1 (en) | Method and apparatus for controlling the adsorption of a liquid sample through an absorbent layer | |
| JPH0735747A (en) | Manufacture of dry analytic element for measuring multiple items | |
| WO1998010283A1 (en) | Sample protective container integral with body fluid separating sheet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FPAY | Fee payment |
Year of fee payment: 8 |
|
| FPAY | Fee payment |
Year of fee payment: 12 |
|
| AS | Assignment |
Owner name: LXN CORPORATION, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NELSON, ERIC M.;WHITE, TODD C.;SIGNING DATES FROM 19980602 TO 19980604;REEL/FRAME:044635/0479 |
|
| AS | Assignment |
Owner name: DIABETES DIAGNOSTICS, INC., NEW JERSEY Free format text: MERGER AND CHANGE OF NAME;ASSIGNORS:LXN CORPORATION;INTEG INCORPORATED;DIABETES DIAGNOSTICS, INC.;REEL/FRAME:044648/0758 Effective date: 20170918 |
|
| AS | Assignment |
Owner name: LIFESCAN SCOTLAND LIMITED, UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DIABETES DIAGNOSTICS, INC.;REEL/FRAME:044701/0018 Effective date: 20180123 |
|
| AS | Assignment |
Owner name: BANK OF AMERICA, N.A., AS COLLATERAL AGENT, NORTH CAROLINA Free format text: SECURITY AGREEMENT;ASSIGNOR:LIFESCAN IP HOLDINGS, LLC;REEL/FRAME:047179/0150 Effective date: 20181001 Owner name: BANK OF AMERICA, N.A., AS COLLATERAL AGENT, NORTH Free format text: SECURITY AGREEMENT;ASSIGNOR:LIFESCAN IP HOLDINGS, LLC;REEL/FRAME:047179/0150 Effective date: 20181001 |
|
| AS | Assignment |
Owner name: BANK OF AMERICA, N.A., AS COLLATERAL AGENT, NORTH CAROLINA Free format text: SECURITY AGREEMENT;ASSIGNOR:LIFESCAN IP HOLDINGS, LLC;REEL/FRAME:047186/0836 Effective date: 20181001 Owner name: BANK OF AMERICA, N.A., AS COLLATERAL AGENT, NORTH Free format text: SECURITY AGREEMENT;ASSIGNOR:LIFESCAN IP HOLDINGS, LLC;REEL/FRAME:047186/0836 Effective date: 20181001 |
|
| AS | Assignment |
Owner name: CILAG GMBH INTERNATIONAL, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LIFESCAN SCOTLAND LTD.;REEL/FRAME:050839/0634 Effective date: 20181001 Owner name: LIFESCAN IP HOLDINGS, LLC, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CILAG GMBH INTERNATIONAL;REEL/FRAME:050840/0006 Effective date: 20181001 |
|
| AS | Assignment |
Owner name: CILAG GMBH INTERNATIONAL, SWITZERLAND Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE DELETING PROPERTY NUMBER 6990849, 7169116, 7351770, 7462265,7468125, 7572356, 8093903, 8486245, 8066866 AND ADD 10431140 PREVIOUSLY RECORDED AT REEL: 050839 FRAME: 0634. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNOR:LIFESCAN SCOTLAND LTD.;REEL/FRAME:064656/0141 Effective date: 20181001 |
|
| AS | Assignment |
Owner name: JOHNSON & JOHNSON CONSUMER INC., NEW JERSEY Free format text: RELEASE OF SECOND LIEN PATENT SECURITY AGREEMENT RECORDED OCT. 3, 2018, REEL/FRAME 047186/0836;ASSIGNOR:BANK OF AMERICA, N.A.;REEL/FRAME:064206/0176 Effective date: 20230627 Owner name: JANSSEN BIOTECH, INC., PENNSYLVANIA Free format text: RELEASE OF SECOND LIEN PATENT SECURITY AGREEMENT RECORDED OCT. 3, 2018, REEL/FRAME 047186/0836;ASSIGNOR:BANK OF AMERICA, N.A.;REEL/FRAME:064206/0176 Effective date: 20230627 Owner name: LIFESCAN IP HOLDINGS, LLC, CALIFORNIA Free format text: RELEASE OF SECOND LIEN PATENT SECURITY AGREEMENT RECORDED OCT. 3, 2018, REEL/FRAME 047186/0836;ASSIGNOR:BANK OF AMERICA, N.A.;REEL/FRAME:064206/0176 Effective date: 20230627 |